Provectus Biopharmaceuticals Company Profile (NYSE:PVCT)

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals logoProvectus Biopharmaceuticals, Inc. is a development-stage biopharmaceutical company. The Company is engaged in developing pharmaceuticals for oncology and dermatology indications. The Company is focused on developing its prescription drug candidates, PV-10 and PH-10. It is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer and breast cancer. It is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions, such as psoriasis and atopic dermatitis, a type of eczema. In addition to clinical trials, patients enrolled in the expanded access or compassionate use program for PV-10 are also receiving PV-10 treatments for cutaneous and subcutaneous cancer indications. The Company also focuses on over-the-counter (OTC) products and various other non-core technologies. PV-10 is a sterile injectable form of rose bengal disodium (Rose Bengal), for direct injection into tumors.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: PVCT
  • CUSIP:
Key Metrics:
  • Previous Close: $0.02
  • 50 Day Moving Average: $0.018
  • 200 Day Moving Average: $0.068
  • 52-Week Range: $243,895,000.00 - $0.01
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.14
  • P/E Growth: 0.000
  • Market Cap: $4.63M
  • Outstanding Shares: 243,895,000
Additional Links:
Companies Related to Provectus Biopharmaceuticals:

Analyst Ratings

Consensus Ratings for Provectus Biopharmaceuticals (NYSE:PVCT) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Provectus Biopharmaceuticals (NYSE:PVCT)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Provectus Biopharmaceuticals (NYSE:PVCT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/28/2017        
5/10/2016Q116($0.04)ViewListenView Earnings Details
3/30/2016Q415($0.05)$1.08 millionViewListenView Earnings Details
11/5/2015Q315($0.03)$1.08 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Provectus Biopharmaceuticals (NYSE:PVCT)
Current Year EPS Consensus Estimate: $-0.120 EPS
Next Year EPS Consensus Estimate: $-0.140 EPS

Dividends

Dividend History for Provectus Biopharmaceuticals (NYSE:PVCT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Provectus Biopharmaceuticals (NYSE:PVCT)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Provectus Biopharmaceuticals (NYSE:PVCT)
DateHeadline
biz.yahoo.com logoPROVECTUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Dire (NYSE:PVCT)
biz.yahoo.com - February 21 at 5:29 PM
finance.yahoo.com logoProvectus Biopharmaceuticals Will Hold a Business Update Conference Call Thursday – January 5, 2017 at 9 a.m. (EST) (NYSE:PVCT)
finance.yahoo.com - January 3 at 10:04 AM
feeds.reuters.com logoBRIEF-Provectus Biopharmaceuticals terminates Peter Culpepper as interim CEO and COO (NYSE:PVCT)
feeds.reuters.com - December 28 at 6:40 PM
News IconDrug Makers Stocks on Investors' Radar -- Provectus Biopharma, Novartis, TherapeuticsMD, and Tonix Pharma (NYSE:PVCT)
www.kait8.com - December 27 at 9:35 AM
biz.yahoo.com logoPROVECTUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (NYSE:PVCT)
biz.yahoo.com - November 29 at 1:57 PM
4-traders.com logoProvectus Pharmaceuticals : reports 3Q loss (NYSE:PVCT)
www.4-traders.com - November 11 at 9:51 AM
finance.yahoo.com logoProvectus Biopharmaceuticals Reports Third Quarter 2016 Financial Results (NYSE:PVCT)
finance.yahoo.com - November 10 at 6:53 PM
biz.yahoo.com logoPROVECTUS BIOPHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial State (NYSE:PVCT)
biz.yahoo.com - November 10 at 6:53 PM
seekingalpha.com logoProvectus Biopharmaceuticals reports Q3 results (NYSE:PVCT)
seekingalpha.com - November 10 at 6:00 PM
biz.yahoo.com logoPROVECTUS BIOPHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report (NYSE:PVCT)
biz.yahoo.com - November 9 at 6:58 PM
News IconDrug Makers Stocks Under Scanner -- Eli Lilly, Provectus Biopharma, GlaxoSmithKline, and Novartis (NYSE:PVCT)
www.bio-medicine.org - November 8 at 6:46 PM
businesswire.com logoProvectus Biopharmaceuticals to Present at Sidoti’s Fall 2016 Emerging Growth Conference, November 1, 2016 (NYSE:PVCT)
www.businesswire.com - October 27 at 11:55 AM
4-traders.com logoPROVECTUS BIOPHARMACEUTICALS, INC. ( : PVCT) Files An 8-K To Present At Sidoti.. (NYSE:PVCT)
www.4-traders.com - October 27 at 11:55 AM
4-traders.com logoGlobal Cosmetic Surgery Market 2016-2020 - Rise in Medical Tourism will be a Key Trend for Market Growth - Research and Markets (NYSE:PVCT)
www.4-traders.com - October 26 at 10:26 AM
finance.yahoo.com logoTrading in Provectus Biopharmaceuticals Common Stock and Warrants Suspended by NYSE MKT (NYSE:PVCT)
finance.yahoo.com - October 14 at 6:40 PM
streetinsider.com logoNYSE MKT to Suspend Trading of Provectus Biopharma (PVCT) Shares; Will Move to Delist (NYSE:PVCT)
www.streetinsider.com - October 13 at 7:03 PM
News Icon8-K: PROVECTUS BIOPHARMACEUTICALS, INC. (NYSE:PVCT)
www.traderplanet.com - September 28 at 12:06 PM
seekingalpha.com logoProvectus prices equity offering; shares plummet 48% (NYSE:PVCT)
seekingalpha.com - August 25 at 7:08 PM
investors.com logoProvectus announces pricing of public offering to raise $6mln (NYSE:PVCT)
www.proactiveinvestors.com - August 25 at 7:08 PM
sg.finance.yahoo.com logoProvectus reports 2Q loss (NYSE:PVCT)
sg.finance.yahoo.com - August 10 at 10:05 AM
publicnow.com logoProvectus Biopharmaceuticals, Inc. Reports Second Quarter 2016 Financial Results (NYSE:PVCT)
www.publicnow.com - August 9 at 7:15 PM
seekingalpha.com logoProvectus Biopharmaceuticals reports Q2 results (NYSE:PVCT)
seekingalpha.com - August 9 at 5:19 PM
finance.yahoo.com logoProvectus Biopharmaceuticals Will Hold Its 2016 Second Quarter Business Update Conference Call on Wednesday, … (NYSE:PVCT)
finance.yahoo.com - July 20 at 9:50 AM
seekingalpha.com logoProvectus Biopharma establishes Australian Subsidiary (NYSE:PVCT)
seekingalpha.com - July 14 at 10:37 AM
publicnow.com logoProvectus Biopharmaceuticals Will Present at 2016 BIO International Convention in San Francisco, CA (NYSE:PVCT)
www.publicnow.com - June 7 at 7:08 AM
publicnow.com logoProvectus Biopharmaceuticals Launches Newly Redesigned Website and Official Facebook Page (NYSE:PVCT)
www.publicnow.com - June 1 at 8:03 AM

Social

What is Provectus Biopharmaceuticals' stock symbol?

Provectus Biopharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "PVCT."

When will Provectus Biopharmaceuticals announce their earnings?

Provectus Biopharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March, 28th 2017.

How do I buy Provectus Biopharmaceuticals stock?

Shares of Provectus Biopharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Provectus Biopharmaceuticals stock cost?

One share of Provectus Biopharmaceuticals stock can currently be purchased for approximately $0.02.

Provectus Biopharmaceuticals (NYSE:PVCT) Chart for Wednesday, February, 22, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Provectus Biopharmaceuticals (NYSE:PVCT)

Earnings History Chart

Earnings by Quarter for Provectus Biopharmaceuticals (NYSE:PVCT)

Dividend History Chart

Dividend Payments by Quarter for Provectus Biopharmaceuticals (NYSE:PVCT)

Last Updated on 2/22/2017 by MarketBeat.com Staff